SCYNEXIS

SCYX · NASDAQ

$3.80+$0.14 (+3.83%)TodayMarket closed · Oct 20, 5:27 PM ET

Prev close $3.66

Latest news

Press releaseOct 6, 7:30 AM ETGlobe Newswire
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Press releaseSep 28, 7:30 AM ETGlobe Newswire
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
Press releaseSep 22, 8:00 AM ETGlobe Newswire
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
Press releaseSep 15, 8:00 AM ETGlobe Newswire
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
NewsAug 26, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsAug 10, 4:45 PM ET
SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate
Press releaseAug 10, 4:30 PM ETGlobe Newswire
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NewsJul 31, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseJun 30, 8:00 AM ETGlobe Newswire
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NewsMay 26, 8:47 AM ETRishabh Mishra
Stock Market Today: S&P 500, Dow, Nasdaq Futures Up Amid US 'Defensive Strikes' On Iran— Elbit Systems, Intuitive Machines, Zscaler In Focus (UPDATED)
NewsMay 26, 2:13 AM ETAvi Kapoor
AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday
Press releaseMay 22, 4:15 PM ETGlobe Newswire
SCYNEXIS Announces One-for-Eight Reverse Stock Split
Press releaseMay 11, 4:23 PM ETGlobe Newswire
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseMar 31, 7:06 AM ETBusiness Wire
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Press releaseMar 31, 6:45 AM ETGlobe Newswire
SCYNEXIS Announces $40.0 Million Private Placement
NewsMar 6, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMar 4, 4:48 PM ET
SCYNEXIS Q4 Earnings Assessment
NewsMar 4, 4:40 PM ET
SCYNEXIS Q4 EPS $0.25 Beats $0.13 Estimate, Sales $18.646M Beat $8.100M Estimate
NewsNov 20, 4:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsOct 2, 8:09 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

12 Health Care Stocks Moving In Wednesday's Intraday Session

SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Friday's Intraday Session

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Stock Market Today: S&P 500, Dow, Nasdaq Futures Up Amid US 'Defensive Strikes' On Iran— Elbit Systems, Intuitive Machines, Zscaler In Focus (UPDATED)

AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces $40.0 Million Private Placement

12 Health Care Stocks Moving In Friday's After-Market Session

SCYNEXIS Q4 Earnings Assessment

SCYNEXIS Q4 EPS $0.25 Beats $0.13 Estimate, Sales $18.646M Beat $8.100M Estimate

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session